Matteo Levisetti
Hoofd Techniek/Wetenschap/O&O bij CUE BIOPHARMA, INC.
Vermogen: 15 045 $ op 31-05-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Daniel Passeri | M | 63 | 8 jaar | |
| Peter Kiener | M | 72 | 8 jaar | |
| Frank Morich | M | 69 | 6 jaar | |
| Kerri-Ann Millar | F | 54 | 7 jaar | |
| Fred Driscoll | M | 73 | 6 jaar | |
| Patrick Verheyen | M | 64 | 1 jaar | |
| Marie Campinell | F | - | - | |
| Colin Sandercock | M | 67 | 7 jaar | |
| Anish Suri | M | 50 | 6 jaar | |
| Pamela Garzone | M | 70 | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Frank Tufaro | M | 69 |
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | 9 jaar |
| Mark Gergen | M | 61 | 3 jaar | |
| Cameron Gray | M | 53 | 7 jaar | |
| Barry Simon | M | 59 | - | |
| Albert Hwang | M | - |
Pritzker School of Medicine
| 5 jaar |
| Ronald D. Seidel | M | - | 8 jaar | |
| Temre Johnson | M | - | 5 jaar | |
| Aaron Fletcher | M | 44 | 4 jaar | |
| Marcy Graham | F | 57 | - | |
| William Ringo | M | 78 | 2 jaar | |
| Tamar Howson | F | 75 | 3 jaar | |
| Bruce Carter | M | 80 | 8 jaar | |
| Chris LeMasters | M | - | 4 jaar | |
| Stephen Dilly | M | 64 |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | - |
| Claire S. Padgett | M | - | 1 jaar | |
| Joseph Luis Damasio | M | 49 | 1 jaar | |
| Kenneth J. Pienta | M | 64 | 6 jaar | |
| Jay Chen | M | - |
Pritzker School of Medicine
| 2 jaar |
| Thomas Fisher | M | - |
Pritzker School of Medicine
| 5 jaar |
| Melinda Ring | F | - |
Pritzker School of Medicine
| 4 jaar |
| Pat Nasshorn | F | 66 | 2 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 31 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Matteo Levisetti
- Persoonlijk netwerk
